UC-MSCs Secretome Induces Proliferation of CD4+ T Cells, CD8+ T Cells, NK Cells, and Increases sPD-1 Levels in Severe COVID-19’s Whole Blood
Abstract
Background: Clinical features of severe coronavirus disease 2019 (COVID-19) predominantly include respiratory symptoms and exacerbated multi-organ complications, especially in patients with comorbidities. Cellular immunity, including lymphocytes, is a critical factor in combating SARS-CoV-2 infection. However, immune dysregulation occurs in severe COVID-19 patients, characterized by cytokine storm and lymphopenia. The effectiveness of mesenchymal stem cell (MSC) therapies for COVID-19 is being assessed. The secretome released by MSC functions similarly to the cells themselves as an immunomodulator, offering potential advantages in terms of safety and cost-effectiveness. This study was conducted to assess the effect of umbilical cord MSC-derived (UC-MSC) secretome treatment on lymphocyte count and soluble programmed cell death-1 (sPD-1) levels in severe COVID-19 patient's whole blood.
Materials and methods: Twelve whole blood samples from healthy individuals and severe COVID-19 patients were analyzed for lymphocyte count and functional activation using flow cytometry, along with sPD-1 level measurement in pre-treatment and post-secretome conditions.
Results: The lymphocyte count in severe COVID-19 patients was significantly decreased, particularly for T cells and NK cells, indicating lymphopenia. Following secretome treatment, CD4+ T cell counts significantly increased compared to pre-treatment, although this change was not significant in the negative control group. Additionally, there was a minimal reduction in B cell count and an increase in sPD-1 levels. Elevated sPD-1 may alleviate T cell exhaustion by interfering with PD-1 binding to programmed death-ligand 1 (PD-L1).
Conclusion: Administration of UC-MSC secretome to the whole blood of severe COVID-19 patients suggested immune improvement, with significant increases in CD4+ T cell counts, enhanced B cell survival, and elevated sPD-1 levels.
Keywords: COVID-19, cellular immunity, lymphocytes, secretome, MSC
Full Text:
PDFReferences
Alipoor SD, Mortaz E, Jamaati H, Tabarsi P, Bayram H, Varahram M, et al. COVID-19: Molecular and cellular response. Front Cell Infect Microbiol. 2021; 11: 563085, CrossRef.
Mahmoodpoor A, Hosseini M, Soltani-Zangbar S, Sanaie S, Aghebati-Maleki L, Saghaleini SH, et al. Reduction and exhausted features of T lymphocytes under serological changes, and prognostic factors in COVID-19 progression. Mol Immunol. 2021; 138: 121-7, CrossRef.
Alsayb MA, Alsamiri ADD, Makhdoom HQ, Alwasaidi T, Osman HM, Mahallawi WH. Prolonged humoral and cellular immunity in COVID-19-recovered patients. Saudi J Biol Sci. 2021; 28(7): 4010-5, CrossRef.
Hosseini A, Esmaeili Gouvarchin Ghaleh H, Aghamollaei H, Fasihi Ramandi M, Alishiri G, Shahriary A, et al. Evaluation of Th1 and Th2 mediated cellular and humoral immunity in patients with COVID-19 following the use of melatonin as an adjunctive treatment. Eur J Pharmacol. 2021; 904: 174193, CrossRef.
Antonsen KW, Hviid CVB, Hagensen MK, Sørensen BS, Møller HJ. Soluble PD-1 (sPD-1) is expressed in human macrophages. Cell Immunol. 2021; 369: 104435, CrossRef.
Jubel JM, Barbati ZR, Burger C, Wirtz DC, Schildberg FA. The role of PD-1 in acute and chronic infection. Front Immunol. 2020; 11: 487, CrossRef.
Mahajan A, Bhattacharyya S. A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients. Biomed J. 2021; 44(1): 63-73, CrossRef.
Chouw A, Milanda T, Sartika CR, Kirana MN, Halim D, Faried A. Potency of mesenchymal stem cell and its secretome in treating COVID-19. Regen Eng Transl Med. 2022; 8(1): 43-54, CrossRef.
Song N, Wakimoto H, Rossignoli F, Bhere D, Chen RCK siong, Khalsa JK, et al. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. 2021; 39(6): 707-22, CrossRef.
Ahangar P, Mills SJ, Cowin AJ. Mesenchymal stem cell secretome as an emerging cell-free alternative for improving wound repair. Int J Mol Sci. 2020; 21(19): 1-15, CrossRef.
Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19 : immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020; 5(128): 1-8, CrossRef.
Beghini DG, Horita SI, Henriques-Pons A. Mesenchymal stem cells in the treatment of COVID-19, a promising future. Cells. 2021; 10(10): 2588, CrossRef.
Lai KL, Hu FC, Wen FY, Chen JJ. Lymphocyte count is a universal predictor of health outcomes in COVID-19 patients before mass vaccination: A meta-analytical study. J Glob Health. 2022; 12: 05041, CrossRef.
Townsend L, Dyer AH, Naughton A, Imangaliyev S, Dunne J, Kiersey R, et al. Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. Heliyon. 2022; 8(4): e09230, CrossRef.
Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021; 10(5): 660-73, CrossRef.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5): 2620-9, CrossRef.
Ahmadi E, Bagherpour Z, Zarei E, Omidkhoda A. Pathological effects of SARS-CoV-2 on hematological and immunological cells: Alterations in count, morphology, and function. Pathol Res Pract. 2022; 231: 153782, CrossRef.
Witkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones TC, Heinrich F, et al. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021; 600(7888): 295-301, CrossRef.
Bonifacius A, Tischer-zimmermann S, Dragon AC, Witzke O, Blasczyk R, Eiz-vesper B, et al. Article COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses ll Article COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021; 54(2): 340-54.e6, CrossRef.
Sosa-Hernández VA, Torres-Ruíz J, Cervantes-Díaz R, Romero-Ramírez S, Páez-Franco JC, Meza-Sánchez DE, et al. B cell subsets as severity-associated signatures in COVID-19 patients. Front Immunol. 2020; 11: 611004, CrossRef.
Laidlaw BJ, Ellebedy AH. The germinal centre B cell response to SARS-CoV-2. Nat Rev Immunol. 2022; 22(1): 7-18, CrossRef.
Liu Y, Tan W, Chen H, Zhu Y, Wan L, Jiang K, et al. Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19. BMC Infect Dis. 2021; 21(1): 1-10, CrossRef.
Olea B, Albert E, Torres I, Amat P, Remigia MJ, Gozalbo-Rovira R, et al. Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients. J Clin Virol. 2021; 142: 104943, CrossRef.
Delshad M, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Poopak B, Shokouhi S, Bashash D. Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity. Int Immunopharmacol. 2021; 99: 107995, CrossRef.
Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell. 2020; 183(1): 143-57.e13, CrossRef.
Fang Y, Lao P, Tang L, Chen J, Chen Y, Sun L, et al. Mechanisms of potential therapeutic utilization of mesenchymal stem cells in COVID-19 Treatment. Cell Transplant. 2023; 32: 9636897231184611, CrossRef.
Chen D, Tang TX, Deng H, Yang XP, Tang ZH. Interleukin-7 biology and its effects on immune cells: Mediator of generation, differentiation, survival, and homeostasis. Front Immunol. 2021; 12: 747324, CrossRef.
Widowati W, Faried A, Kusuma H, Hermanto Y, Harsono A, Djuwantono T. Allogeneic mesenchymal stem cells and its conditioned medium as a potential adjuvant therapy for COVID-19. Mol Cell Biomed Sci. 2023; 7(1): 1-9, CrossRef.
Han Y, Yang J, Fang J, Zhou Y, Candi E, Wang J, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther. 2022; 7(1): 92, CrossRef.
Wang Z. Regulation of cell cycle progression by growth factor-induced cell signaling. Cells. 2021; 10(12): 3327, CrossRef.
Zhu R, Yan T, Feng Y, Liu Y, Cao H, Peng G, et al. Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms. Cell Res. 2021; 31(12): 1244-62, CrossRef.
Bukreieva T, Svitina H, Nikulina V, Vega A, Chybisov O, Shablii I, et al. Treatment of acute respiratory distress syndrome caused by COVID-19 with human umbilical cord mesenchymal stem cells. Int J Mol Sci. 2023; 24(5): 4435, CrossRef.
Loretelli C, Abdelsalam A, D'Addio F, Nasr M Ben, Assi E, Usuelli V, et al. PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. JCI Insight. 2021; 6(24): 1-13, CrossRef.
Khan M, Zhao Z, Arooj S, Fu Y, Liao G. Soluble PD-1: Predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol. 2020; 11: 587460, CrossRef.
León CP De, López-casado MA, Lorite P, Palomeque T, Torres MI. Dysregulation of the PD-1 / PD-L1 pathway contributes to the pathogenesis of celiac disease. Cell Mol Immunol. 2019; 16(9): 777-9, CrossRef.
Shyer JA, Flavell RA, Bailis W. Metabolic signaling in T cells. Cell Res. 2020; 30(8): 649-59, CrossRef.
DOI: https://doi.org/10.21705/mcbs.v9i1.538
Copyright (c) 2025 Cell and BioPharmaceutical Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
Cell and BioPharmaceutical Institute
